Q2 EPS Estimate for United Therapeutics Lifted by Analyst

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Equities research analysts at Leerink Partnrs increased their Q2 2025 EPS estimates for shares of United Therapeutics in a research note issued on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will post earnings per share of $8.08 for the quarter, up from their prior forecast of $7.20. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. Leerink Partnrs also issued estimates for United Therapeutics' Q4 2025 earnings at $6.75 EPS.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. During the same period last year, the company posted $6.17 EPS. The firm's quarterly revenue was up 17.2% on a year-over-year basis.

A number of other research analysts also recently weighed in on the company. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. JPMorgan Chase & Co. reduced their price target on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. Bank of America lowered their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research report on Wednesday. Finally, Morgan Stanley upped their price objective on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research note on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $393.08.

United Therapeutics Price Performance

NASDAQ UTHR traded up $9.67 on Monday, hitting $286.14. 1,060,215 shares of the company were exchanged, compared to its average volume of 452,502. United Therapeutics has a twelve month low of $266.98 and a twelve month high of $417.82. The firm has a market capitalization of $12.91 billion, a P/E ratio of 12.57, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. The company's 50 day moving average price is $300.54 and its 200-day moving average price is $332.08.

Insider Buying and Selling

In related news, CFO James Edgemond sold 12,000 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the sale, the chief financial officer now directly owns 8,118 shares of the company's stock, valued at approximately $2,641,353.66. This represents a 59.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the transaction, the director now owns 8,480 shares in the company, valued at $2,703,424. This trade represents a 22.77% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 68,500 shares of company stock worth $20,828,390. 10.30% of the stock is currently owned by insiders.

Institutional Trading of United Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC lifted its holdings in shares of United Therapeutics by 1,657.8% during the first quarter. Acadian Asset Management LLC now owns 179,205 shares of the biotechnology company's stock worth $55,217,000 after buying an additional 169,010 shares during the last quarter. Geneos Wealth Management Inc. increased its position in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 85 shares during the period. Intech Investment Management LLC raised its stake in United Therapeutics by 1.4% during the 1st quarter. Intech Investment Management LLC now owns 30,935 shares of the biotechnology company's stock valued at $9,536,000 after purchasing an additional 442 shares during the last quarter. Capital Impact Advisors LLC bought a new stake in United Therapeutics in the 1st quarter valued at $6,508,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in United Therapeutics by 10.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 257,662 shares of the biotechnology company's stock worth $79,429,000 after purchasing an additional 25,289 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.